TABLE 3.
AEs possibly or probably attributable to curcumin by arm and overall for patients with metastatic colorectal cancer receiving FOLFOX or CUFOX treatment1
| FOLFOX | CUFOX | Total | |
|---|---|---|---|
| Abdominal pain | 0 | 2 (3.4) | 2 (3.4) |
| Acute kidney injury | 0 | 2 (3.4) | 2 (3.4) |
| Anorexia | 0 | 4 (6.8) | 4 (6.8) |
| Bloating | 0 | 2 (3.4) | 2 (3.4) |
| Constipation | 0 | 5 (8.5) | 5 (8.5) |
| Diarrhea | 0 | 10 (17.0) | 10 (17.0) |
| Dry mouth | 0 | 2 (3.4) | 2 (3.4) |
| Dyspepsia | 0 | 7 (11.9) | 7 (11.9) |
| Flatulence | 0 | 2 (3.4) | 2 (3.4) |
| Nausea | 0 | 8 (13.6) | 8 (13.6) |
| Oral mucositis | 0 | 6 (10.2) | 6 (10.2) |
| Vomiting | 0 | 5 (8.5) | 5 (8.5) |
1
Values represent n (%) of all AEs possibly or probably attributable to curcumin in each arm and overall for the intention-to-treat population, reported for those events that constituted ≥2.5% of all AEs. The number of patients on FOLFOX and CUFOX was 9 and 18, respectively. AE, adverse event; CUFOX, folinic acid/5-fluorouracil/oxaliplatin +2 g oral curcumin/d; FOLFOX, folinic acid/5-fluorouracil/oxaliplatin.